Commentary: Why the US FDA is taking a wait-and-see attitude on booster shots for US public

Commentary: Why the US FDA is taking a wait-and-see attitude on booster shots for US public

21/9/2021 1:08:00 AM

Commentary: Why the US FDA is taking a wait-and-see attitude on booster shots for US public

The US FDA panel had to weigh the risks and benefits surrounding booster shots, says an immunologist.

of Pfizer’s mRNA vaccine to the general public – a move that will likely disappoint some public health experts pushing for a third dose to help slow the spread of COVID-19.In a 16-2 vote on Friday (Sep 17), an independent committee of physicians, scientists and public health experts recommended against full use of the third dose of the vaccine, which now goes by the brand name Comirnaty.

Why was Singapore excluded from the upcoming US Summit for Democracy? Singapore delivers more than 100,000 doses of COVID-19 vaccines to Johor Singapore authorities clarifying if VTL travellers to South Korea will need to do 10-day quarantine

However, the panel did recommend the shot for Americans aged 65 and older or those at high risk for severe COVID-19.In recommending against the shot for the general public, the committee cited reasons such as lack of sufficient safety data in younger age groups as well as indications that the initial doses still seem to be providing robust protection against severe illness leading to hospitalisation and death.

The panel also agreed in a poll – but not a formal vote – that boosters would be beneficial for certain populations, such as healthcare workers and others at high risk for occupational exposure.Although the vote is not binding, it is likely that it will form the basis of a formal FDA recommendation.

The push for a booster was predictable, although the outcome of the vote was always far from certain. Over the past year, significant research and public reporting have focused on the durability of the immune response following the first and second doses of the COVID-19 mRNA vaccines.

This work has been critical to scientists’ understanding of how long the immune responses from vaccination can provide protection, and whether that protection extends to new and emerging variants of the SARS-CoV-2 virus.Will a vaccine mandate address plateauing vaccination rates? Two infectious disease experts weigh in on Heart of the Matter:

WANING ANTIBODIESThe good news is that the mRNA vaccines do appear to provide continued efficacy against serious illness or death caused by new strains of the coronavirus, including the highly infectious Delta variant.But data on the longevity of this protection has been more mixed and is still limited in scope.

Although there are indications that immune “memory” is being established in vaccine recipients – almost certainly providing partial protection in the long term – the antibodies responsible for stopping the virus in its tracks before infection occurs appear to wane over the course of months following the second dose.

You Can Now Staycay At S'pore Zoo In Air-Con Tents — Includes Meals, Guided Tours & Waking Up Next To A Reservoir 'No need to panic' over Omicron variant: Africa CDC You can spend a night at the Home Alone house for just US$25

This is not surprising to immunologists and does not mean the vaccine isn’t working. Antibodies wane as a normal course of an immune response to any vaccine.This is why you need a tetanus booster every decade or so, and why the measles, mumps and rubella vaccine is administered in three doses – not just two.

The question is simply how fast antibodies decline, and at what point they no longer provide adequate protection. At that point, an additional dose of the vaccine is recommended to boost the antibody numbers back up to protective levels.Related:Why Singapore is still in a transition stage towards endemic living: Infectious disease experts explain

In this case, widespread reporting of breakthrough infections – infections in individuals who have been fully vaccinated – and research citing the possibility of declining immunity in populations vaccinated early in the pandemic brought discussions of the need for boosters quickly to the forefront.

SEPARATING POLITICS FROM DATAAgainst this backdrop of mixed data, the FDA panel had to weigh the risks and benefits surrounding booster shots.While the third dose of vaccine would have been identical to those already fully approved – and as such deemed safe – they would not be without side effects similar to those seen in the first and second doses.

In addition, serious conditions such as myocarditis – an inflammation of the heart – that have been recorded in rare and isolated cases after the initial vaccine shots will likely occur following the booster as well.This, in addition to a debate around the absolute benefit of a third shot to maintain current protection levels in otherwise healthy vaccinated individuals, has led many public health officials to express concern that the review is premature and risks further confusing and alienating an already divided American public.

With the Biden administration having already publicly backed a third dose for all vaccinated Americans in August, the committee was tasked with separating the politics from the data to weigh in on whether the benefits of a booster shot outweighed the risks to an already-hesitant American public.

After some confusion, Korean embassy says VTL travellers from Singapore exempted from South Korea’s new quarantine rules Hong Kong to launch mobile 'health code' app ahead of China border opening MOH reminding those who’ve had 2 doses of Sinovac-CoronaVac or Sinopharm vaccine to get 3rd dose by Dec 31

In rejecting the proposal, the FDA panel has signalled its confidence in the original vaccination course among healthy individuals, and will wait for additional data before identifying waning antibody levels as a significant threat to public safety.However, its support for boosting those at high risk for exposure to COVID-19 suggests a recognition that additional shots may yet be necessary to fully protect the public at large.

Read more: CNA »

'End of stabilisation phase': Up to 5 fully vaccinated people allowed for social gatherings, dining in from Nov 22

SINGAPORE — From Monday (Nov 22), fully vaccinated people can dine together in groups of up to five, even if they are not from the same household.

Greek PM says climate crisis is with us and cost of ignoring it 'unimaginable'ATHENS: Mediterranean nations must lead the way in addressing climate change, the Greek prime minister said, warning that the cost of doing nothing was unimaginable, with mankind possibly struggling to survive beyond the turn of the next century. Greece, Turkey, Cyprus and Spain were ravaged by wildfi

Body found matching description of US missing woman Gabby Petito: FBIWASHINGTON — US law enforcement said Sunday (Sept 19) a body found in a US national forest in Wyoming, where a search was underway for Gabrielle

Oil down on stronger greenback, rising US rig countMELBOURNE : Oil prices fell on Monday, extending losses from Friday after the U.S. dollar jumped to a three-week high and the U.S. rig count rose, although nearly a quarter of U.S. Gulf of Mexico output remained offline in the wake of two hurricanes. U.S. West Texas Intermediate (WTI) crude futures fell 3

Universal Studios Beijing to draw eager throngs amid uneasy US -China tiesBEIJING : Universal Studios' Beijing resort was set to open its doors to the public on Monday after a two-decade wait, including delays because of COVID-19.The highly-anticipated opening takes place amid U.S.-China relations that have deeply deteriorated in recent years.The park will be U.S.-based

France's OVHcloud prepares for US$ 4.7 billion IPO- WSJFrench cloud computing services provider OVHcloud plans to launch a possible initial public offering as soon as Monday that could value it at more than US$4.7 billion, the Wall Street Journal reported on Sunday, citing people familiar with the matter. The cloud-service provider

US opens probe into 30 million vehicles over air bag inflatorsWASHINGTON: US auto safety investigators have opened a new probe into 30 million vehicles built by nearly two dozen automakers with potentially defective Takata air bag inflators, a government document seen by Reuters shows. The National Highway Traffic Safety Administration (NHTSA) on Friday opened a